カテゴリ： 世界, 医療/バイオ, QYResearch

非筋層浸潤性膀胱がん治療薬の世界市場2023年：膀胱内化学療法、膀胱内免疫療法

■ 英語タイトル：Global Non-muscle Invasive Bladder Cancer Therapeutics Market Research Report 2023

調査会社QYResearch社が発行したリサーチレポート（データ管理コード：QYR23MA7515）■ 発行会社/調査会社：QYResearch
■ 商品コード：QYR23MA7515
■ 発行日：2023年3月
■ 調査対象地域：グローバル
■ 産業分野：医療
■ ページ数：116
■ レポート言語：英語
■ レポート形式：PDF
■ 納品方式：Eメール（受注後2-3営業日）
■ 販売価格オプション（消費税別）
Single User（1名様閲覧用）USD2,900 ⇒換算￥440,800見積依頼/購入/質問フォーム
Multi User（5名様閲覧用）USD4,350 ⇒換算￥661,200見積依頼/購入/質問フォーム
Enterprise License（同一法人内共有可）USD5,800 ⇒換算￥881,600見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能）
※QYResearch社の概要及び新刊レポートはこちらでご確認いただけます。
★グローバルリサーチ資料[非筋層浸潤性膀胱がん治療薬の世界市場2023年：膀胱内化学療法、膀胱内免疫療法]についてメールでお問い合わせはこちら
*** レポート概要（サマリー）***

当調査資料は非筋層浸潤性膀胱がん治療薬のグローバル市場について調査・分析し、世界の非筋層浸潤性膀胱がん治療薬市場概要、市場トレンド、主要企業別競争状況、タイプ別セグメント分析（膀胱内化学療法、膀胱内免疫療法）、用途別セグメント分析（病院、外来手術センター、その他）、地域別市場規模、主要企業のプロファイルなどに関する情報を掲載しています。主要企業としては、F. Hoffmann-La Roche Ltd.、Bristol-Myers Squibb Company、AstraZeneca、Pfizer Inc.、GlaxoSmithKline plc.、Sanofi S.A.、Novartis AG、Eli Lilly and Company、Merck & Co.、Viventia Bio Inc.、Celgene Corporation、Spectrum Pharmaceuticals, Inc.、Herantis Pharma Plc.、Taris Biomedical LLC、Prometic Life Sciences Inc.、Telormediz S.A.、Heat Biologics、Altor BioScience、Ferring B.V.、Cold Genesys Inc.などが含まれています。非筋層浸潤性膀胱がん治療薬のグローバル市場は、2022年にXXX米ドル、2029年にはXXX米ドルに達すると予測され、予測期間の年平均成長率はXXX％です。新型コロナとロシア・ウクライナ戦争の影響は、非筋層浸潤性膀胱がん治療薬市場規模を算出する際に考慮しました。

・非筋層浸潤性膀胱がん治療薬市場の概要
- 非筋層浸潤性膀胱がん治療薬の種類別セグメント
- 世界の非筋層浸潤性膀胱がん治療薬市場規模：タイプ別分析（膀胱内化学療法、膀胱内免疫療法）
- 非筋層浸潤性膀胱がん治療薬の用途別セグメント
- 世界の非筋層浸潤性膀胱がん治療薬市場規模：用途別分析（病院、外来手術センター、その他）
- 世界の非筋層浸潤性膀胱がん治療薬市場規模予測（2018年-2029年）

・非筋層浸潤性膀胱がん治療薬市場の成長トレンド
- 非筋層浸潤性膀胱がん治療薬の地域別市場規模（2018年-2029年）
- 非筋層浸潤性膀胱がん治療薬市場ダイナミクス
- 非筋層浸潤性膀胱がん治療薬の業界動向
- 非筋層浸潤性膀胱がん治療薬市場の成長ドライバ、課題、阻害要因

・主要企業別競争状況
- 企業別市場シェア
- 世界の主要企業、業界ランキング分析
- 市場への参入、M＆A動向

・種類別セグメント：膀胱内化学療法、膀胱内免疫療法
- 世界の非筋層浸潤性膀胱がん治療薬のタイプ別市場規模（2018年-2023年）
- 世界の非筋層浸潤性膀胱がん治療薬のタイプ別市場規模（2024年-2029年）

・用途別セグメント：病院、外来手術センター、その他
- 世界の非筋層浸潤性膀胱がん治療薬の用途別市場規模（2018年-2023年）
- 世界の非筋層浸潤性膀胱がん治療薬の用途別市場規模（2024年-2029年）

・非筋層浸潤性膀胱がん治療薬の地域別市場規模
- 北米の非筋層浸潤性膀胱がん治療薬市場規模（2018年-2029年）
- 米国の非筋層浸潤性膀胱がん治療薬市場規模（2018年-2029年）
- ヨーロッパの非筋層浸潤性膀胱がん治療薬市場規模（2018年-2029年）
- アジア太平洋の非筋層浸潤性膀胱がん治療薬市場規模（2018年-2029年）
- 中国の非筋層浸潤性膀胱がん治療薬市場規模（2018年-2029年）
- 日本の非筋層浸潤性膀胱がん治療薬市場規模（2018年-2029年）
- 韓国の非筋層浸潤性膀胱がん治療薬市場規模（2018年-2029年）
- インドの非筋層浸潤性膀胱がん治療薬市場規模（2018年-2029年）
- オーストラリアの非筋層浸潤性膀胱がん治療薬市場規模（2018年-2029年）
- 中南米の非筋層浸潤性膀胱がん治療薬市場規模（2018年-2029年）
- 中東・アフリカの非筋層浸潤性膀胱がん治療薬市場規模（2018年-2029年）

・主要企業のプロファイル：企業情報、事業概要、売上、動向
F. Hoffmann-La Roche Ltd.、Bristol-Myers Squibb Company、AstraZeneca、Pfizer Inc.、GlaxoSmithKline plc.、Sanofi S.A.、Novartis AG、Eli Lilly and Company、Merck & Co.、Viventia Bio Inc.、Celgene Corporation、Spectrum Pharmaceuticals, Inc.、Herantis Pharma Plc.、Taris Biomedical LLC、Prometic Life Sciences Inc.、Telormediz S.A.、Heat Biologics、Altor BioScience、Ferring B.V.、Cold Genesys Inc.

・アナリストの観点/結論

・調査手法と情報源

Highlights
The global Non-muscle Invasive Bladder Cancer Therapeutics market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
North American market for Non-muscle Invasive Bladder Cancer Therapeutics is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Non-muscle Invasive Bladder Cancer Therapeutics is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The global market for Non-muscle Invasive Bladder Cancer Therapeutics in Hospital is estimated to increase from $ million in 2023 to $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global companies of Non-muscle Invasive Bladder Cancer Therapeutics include F. Hoffmann-La Roche Ltd., Bristol-Myers Squibb Company, AstraZeneca, Pfizer Inc., GlaxoSmithKline plc., Sanofi S.A., Novartis AG, Eli Lilly and Company and Merck & Co., etc. In 2022, the world’s top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Non-muscle Invasive Bladder Cancer Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Non-muscle Invasive Bladder Cancer Therapeutics.
The Non-muscle Invasive Bladder Cancer Therapeutics market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Non-muscle Invasive Bladder Cancer Therapeutics market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Non-muscle Invasive Bladder Cancer Therapeutics companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.
By Company
F. Hoffmann-La Roche Ltd.
Bristol-Myers Squibb Company
AstraZeneca
Pfizer Inc.
GlaxoSmithKline plc.
Sanofi S.A.
Novartis AG
Eli Lilly and Company
Merck & Co.
Viventia Bio Inc.
Celgene Corporation
Spectrum Pharmaceuticals, Inc.
Herantis Pharma Plc.
Taris Biomedical LLC
Prometic Life Sciences Inc.
Telormediz S.A.
Heat Biologics
Altor BioScience
Ferring B.V.
Cold Genesys Inc.
Segment by Type
Intravesical Chemotherapy
Intravesical Immunotherapy
Segment by Application
Hospital
Ambulatory Surgery Center
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Non-muscle Invasive Bladder Cancer Therapeutics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

*** レポート目次（コンテンツ）***

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Non-muscle Invasive Bladder Cancer Therapeutics Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Intravesical Chemotherapy
1.2.3 Intravesical Immunotherapy
1.3 Market by Application
1.3.1 Global Non-muscle Invasive Bladder Cancer Therapeutics Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Hospital
1.3.3 Ambulatory Surgery Center
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Non-muscle Invasive Bladder Cancer Therapeutics Market Perspective (2018-2029)
2.2 Non-muscle Invasive Bladder Cancer Therapeutics Growth Trends by Region
2.2.1 Global Non-muscle Invasive Bladder Cancer Therapeutics Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Non-muscle Invasive Bladder Cancer Therapeutics Historic Market Size by Region (2018-2023)
2.2.3 Non-muscle Invasive Bladder Cancer Therapeutics Forecasted Market Size by Region (2024-2029)
2.3 Non-muscle Invasive Bladder Cancer Therapeutics Market Dynamics
2.3.1 Non-muscle Invasive Bladder Cancer Therapeutics Industry Trends
2.3.2 Non-muscle Invasive Bladder Cancer Therapeutics Market Drivers
2.3.3 Non-muscle Invasive Bladder Cancer Therapeutics Market Challenges
2.3.4 Non-muscle Invasive Bladder Cancer Therapeutics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Non-muscle Invasive Bladder Cancer Therapeutics Players by Revenue
3.1.1 Global Top Non-muscle Invasive Bladder Cancer Therapeutics Players by Revenue (2018-2023)
3.1.2 Global Non-muscle Invasive Bladder Cancer Therapeutics Revenue Market Share by Players (2018-2023)
3.2 Global Non-muscle Invasive Bladder Cancer Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Non-muscle Invasive Bladder Cancer Therapeutics Revenue
3.4 Global Non-muscle Invasive Bladder Cancer Therapeutics Market Concentration Ratio
3.4.1 Global Non-muscle Invasive Bladder Cancer Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Non-muscle Invasive Bladder Cancer Therapeutics Revenue in 2022
3.5 Non-muscle Invasive Bladder Cancer Therapeutics Key Players Head office and Area Served
3.6 Key Players Non-muscle Invasive Bladder Cancer Therapeutics Product Solution and Service
3.7 Date of Enter into Non-muscle Invasive Bladder Cancer Therapeutics Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Non-muscle Invasive Bladder Cancer Therapeutics Breakdown Data by Type
4.1 Global Non-muscle Invasive Bladder Cancer Therapeutics Historic Market Size by Type (2018-2023)
4.2 Global Non-muscle Invasive Bladder Cancer Therapeutics Forecasted Market Size by Type (2024-2029)
5 Non-muscle Invasive Bladder Cancer Therapeutics Breakdown Data by Application
5.1 Global Non-muscle Invasive Bladder Cancer Therapeutics Historic Market Size by Application (2018-2023)
5.2 Global Non-muscle Invasive Bladder Cancer Therapeutics Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Non-muscle Invasive Bladder Cancer Therapeutics Market Size (2018-2029)
6.2 North America Non-muscle Invasive Bladder Cancer Therapeutics Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Non-muscle Invasive Bladder Cancer Therapeutics Market Size by Country (2018-2023)
6.4 North America Non-muscle Invasive Bladder Cancer Therapeutics Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Non-muscle Invasive Bladder Cancer Therapeutics Market Size (2018-2029)
7.2 Europe Non-muscle Invasive Bladder Cancer Therapeutics Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Non-muscle Invasive Bladder Cancer Therapeutics Market Size by Country (2018-2023)
7.4 Europe Non-muscle Invasive Bladder Cancer Therapeutics Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Non-muscle Invasive Bladder Cancer Therapeutics Market Size (2018-2029)
8.2 Asia-Pacific Non-muscle Invasive Bladder Cancer Therapeutics Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Non-muscle Invasive Bladder Cancer Therapeutics Market Size by Region (2018-2023)
8.4 Asia-Pacific Non-muscle Invasive Bladder Cancer Therapeutics Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Non-muscle Invasive Bladder Cancer Therapeutics Market Size (2018-2029)
9.2 Latin America Non-muscle Invasive Bladder Cancer Therapeutics Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Non-muscle Invasive Bladder Cancer Therapeutics Market Size by Country (2018-2023)
9.4 Latin America Non-muscle Invasive Bladder Cancer Therapeutics Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Non-muscle Invasive Bladder Cancer Therapeutics Market Size (2018-2029)
10.2 Middle East & Africa Non-muscle Invasive Bladder Cancer Therapeutics Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Non-muscle Invasive Bladder Cancer Therapeutics Market Size by Country (2018-2023)
10.4 Middle East & Africa Non-muscle Invasive Bladder Cancer Therapeutics Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 F. Hoffmann-La Roche Ltd.
11.1.1 F. Hoffmann-La Roche Ltd. Company Detail
11.1.2 F. Hoffmann-La Roche Ltd. Business Overview
11.1.3 F. Hoffmann-La Roche Ltd. Non-muscle Invasive Bladder Cancer Therapeutics Introduction
11.1.4 F. Hoffmann-La Roche Ltd. Revenue in Non-muscle Invasive Bladder Cancer Therapeutics Business (2018-2023)
11.1.5 F. Hoffmann-La Roche Ltd. Recent Development
11.2 Bristol-Myers Squibb Company
11.2.1 Bristol-Myers Squibb Company Company Detail
11.2.2 Bristol-Myers Squibb Company Business Overview
11.2.3 Bristol-Myers Squibb Company Non-muscle Invasive Bladder Cancer Therapeutics Introduction
11.2.4 Bristol-Myers Squibb Company Revenue in Non-muscle Invasive Bladder Cancer Therapeutics Business (2018-2023)
11.2.5 Bristol-Myers Squibb Company Recent Development
11.3 AstraZeneca
11.3.1 AstraZeneca Company Detail
11.3.2 AstraZeneca Business Overview
11.3.3 AstraZeneca Non-muscle Invasive Bladder Cancer Therapeutics Introduction
11.3.4 AstraZeneca Revenue in Non-muscle Invasive Bladder Cancer Therapeutics Business (2018-2023)
11.3.5 AstraZeneca Recent Development
11.4 Pfizer Inc.
11.4.1 Pfizer Inc. Company Detail
11.4.2 Pfizer Inc. Business Overview
11.4.3 Pfizer Inc. Non-muscle Invasive Bladder Cancer Therapeutics Introduction
11.4.4 Pfizer Inc. Revenue in Non-muscle Invasive Bladder Cancer Therapeutics Business (2018-2023)
11.4.5 Pfizer Inc. Recent Development
11.5 GlaxoSmithKline plc.
11.5.1 GlaxoSmithKline plc. Company Detail
11.5.2 GlaxoSmithKline plc. Business Overview
11.5.3 GlaxoSmithKline plc. Non-muscle Invasive Bladder Cancer Therapeutics Introduction
11.5.4 GlaxoSmithKline plc. Revenue in Non-muscle Invasive Bladder Cancer Therapeutics Business (2018-2023)
11.5.5 GlaxoSmithKline plc. Recent Development
11.6 Sanofi S.A.
11.6.1 Sanofi S.A. Company Detail
11.6.2 Sanofi S.A. Business Overview
11.6.3 Sanofi S.A. Non-muscle Invasive Bladder Cancer Therapeutics Introduction
11.6.4 Sanofi S.A. Revenue in Non-muscle Invasive Bladder Cancer Therapeutics Business (2018-2023)
11.6.5 Sanofi S.A. Recent Development
11.7 Novartis AG
11.7.1 Novartis AG Company Detail
11.7.2 Novartis AG Business Overview
11.7.3 Novartis AG Non-muscle Invasive Bladder Cancer Therapeutics Introduction
11.7.4 Novartis AG Revenue in Non-muscle Invasive Bladder Cancer Therapeutics Business (2018-2023)
11.7.5 Novartis AG Recent Development
11.8 Eli Lilly and Company
11.8.1 Eli Lilly and Company Company Detail
11.8.2 Eli Lilly and Company Business Overview
11.8.3 Eli Lilly and Company Non-muscle Invasive Bladder Cancer Therapeutics Introduction
11.8.4 Eli Lilly and Company Revenue in Non-muscle Invasive Bladder Cancer Therapeutics Business (2018-2023)
11.8.5 Eli Lilly and Company Recent Development
11.9 Merck & Co.
11.9.1 Merck & Co. Company Detail
11.9.2 Merck & Co. Business Overview
11.9.3 Merck & Co. Non-muscle Invasive Bladder Cancer Therapeutics Introduction
11.9.4 Merck & Co. Revenue in Non-muscle Invasive Bladder Cancer Therapeutics Business (2018-2023)
11.9.5 Merck & Co. Recent Development
11.10 Viventia Bio Inc.
11.10.1 Viventia Bio Inc. Company Detail
11.10.2 Viventia Bio Inc. Business Overview
11.10.3 Viventia Bio Inc. Non-muscle Invasive Bladder Cancer Therapeutics Introduction
11.10.4 Viventia Bio Inc. Revenue in Non-muscle Invasive Bladder Cancer Therapeutics Business (2018-2023)
11.10.5 Viventia Bio Inc. Recent Development
11.11 Celgene Corporation
11.11.1 Celgene Corporation Company Detail
11.11.2 Celgene Corporation Business Overview
11.11.3 Celgene Corporation Non-muscle Invasive Bladder Cancer Therapeutics Introduction
11.11.4 Celgene Corporation Revenue in Non-muscle Invasive Bladder Cancer Therapeutics Business (2018-2023)
11.11.5 Celgene Corporation Recent Development
11.12 Spectrum Pharmaceuticals, Inc.
11.12.1 Spectrum Pharmaceuticals, Inc. Company Detail
11.12.2 Spectrum Pharmaceuticals, Inc. Business Overview
11.12.3 Spectrum Pharmaceuticals, Inc. Non-muscle Invasive Bladder Cancer Therapeutics Introduction
11.12.4 Spectrum Pharmaceuticals, Inc. Revenue in Non-muscle Invasive Bladder Cancer Therapeutics Business (2018-2023)
11.12.5 Spectrum Pharmaceuticals, Inc. Recent Development
11.13 Herantis Pharma Plc.
11.13.1 Herantis Pharma Plc. Company Detail
11.13.2 Herantis Pharma Plc. Business Overview
11.13.3 Herantis Pharma Plc. Non-muscle Invasive Bladder Cancer Therapeutics Introduction
11.13.4 Herantis Pharma Plc. Revenue in Non-muscle Invasive Bladder Cancer Therapeutics Business (2018-2023)
11.13.5 Herantis Pharma Plc. Recent Development
11.14 Taris Biomedical LLC
11.14.1 Taris Biomedical LLC Company Detail
11.14.2 Taris Biomedical LLC Business Overview
11.14.3 Taris Biomedical LLC Non-muscle Invasive Bladder Cancer Therapeutics Introduction
11.14.4 Taris Biomedical LLC Revenue in Non-muscle Invasive Bladder Cancer Therapeutics Business (2018-2023)
11.14.5 Taris Biomedical LLC Recent Development
11.15 Prometic Life Sciences Inc.
11.15.1 Prometic Life Sciences Inc. Company Detail
11.15.2 Prometic Life Sciences Inc. Business Overview
11.15.3 Prometic Life Sciences Inc. Non-muscle Invasive Bladder Cancer Therapeutics Introduction
11.15.4 Prometic Life Sciences Inc. Revenue in Non-muscle Invasive Bladder Cancer Therapeutics Business (2018-2023)
11.15.5 Prometic Life Sciences Inc. Recent Development
11.16 Telormediz S.A.
11.16.1 Telormediz S.A. Company Detail
11.16.2 Telormediz S.A. Business Overview
11.16.3 Telormediz S.A. Non-muscle Invasive Bladder Cancer Therapeutics Introduction
11.16.4 Telormediz S.A. Revenue in Non-muscle Invasive Bladder Cancer Therapeutics Business (2018-2023)
11.16.5 Telormediz S.A. Recent Development
11.17 Heat Biologics
11.17.1 Heat Biologics Company Detail
11.17.2 Heat Biologics Business Overview
11.17.3 Heat Biologics Non-muscle Invasive Bladder Cancer Therapeutics Introduction
11.17.4 Heat Biologics Revenue in Non-muscle Invasive Bladder Cancer Therapeutics Business (2018-2023)
11.17.5 Heat Biologics Recent Development
11.18 Altor BioScience
11.18.1 Altor BioScience Company Detail
11.18.2 Altor BioScience Business Overview
11.18.3 Altor BioScience Non-muscle Invasive Bladder Cancer Therapeutics Introduction
11.18.4 Altor BioScience Revenue in Non-muscle Invasive Bladder Cancer Therapeutics Business (2018-2023)
11.18.5 Altor BioScience Recent Development
11.19 Ferring B.V.
11.19.1 Ferring B.V. Company Detail
11.19.2 Ferring B.V. Business Overview
11.19.3 Ferring B.V. Non-muscle Invasive Bladder Cancer Therapeutics Introduction
11.19.4 Ferring B.V. Revenue in Non-muscle Invasive Bladder Cancer Therapeutics Business (2018-2023)
11.19.5 Ferring B.V. Recent Development
11.20 Cold Genesys Inc.
11.20.1 Cold Genesys Inc. Company Detail
11.20.2 Cold Genesys Inc. Business Overview
11.20.3 Cold Genesys Inc. Non-muscle Invasive Bladder Cancer Therapeutics Introduction
11.20.4 Cold Genesys Inc. Revenue in Non-muscle Invasive Bladder Cancer Therapeutics Business (2018-2023)
11.20.5 Cold Genesys Inc. Recent Development
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global Non-muscle Invasive Bladder Cancer Therapeutics Market Size Growth Rate by Type (US$ Million): 2018 VS 2022 VS 2029
Table 2. Key Players of Intravesical Chemotherapy
Table 3. Key Players of Intravesical Immunotherapy
Table 4. Global Non-muscle Invasive Bladder Cancer Therapeutics Market Size Growth by Application (US$ Million): 2018 VS 2022 VS 2029
Table 5. Global Non-muscle Invasive Bladder Cancer Therapeutics Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Table 6. Global Non-muscle Invasive Bladder Cancer Therapeutics Market Size by Region (2018-2023) & (US$ Million)
Table 7. Global Non-muscle Invasive Bladder Cancer Therapeutics Market Share by Region (2018-2023)
Table 8. Global Non-muscle Invasive Bladder Cancer Therapeutics Forecasted Market Size by Region (2024-2029) & (US$ Million)
Table 9. Global Non-muscle Invasive Bladder Cancer Therapeutics Market Share by Region (2024-2029)
Table 10. Non-muscle Invasive Bladder Cancer Therapeutics Market Trends
Table 11. Non-muscle Invasive Bladder Cancer Therapeutics Market Drivers
Table 12. Non-muscle Invasive Bladder Cancer Therapeutics Market Challenges
Table 13. Non-muscle Invasive Bladder Cancer Therapeutics Market Restraints
Table 14. Global Non-muscle Invasive Bladder Cancer Therapeutics Revenue by Players (2018-2023) & (US$ Million)
Table 15. Global Non-muscle Invasive Bladder Cancer Therapeutics Market Share by Players (2018-2023)
Table 16. Global Top Non-muscle Invasive Bladder Cancer Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Non-muscle Invasive Bladder Cancer Therapeutics as of 2022)
Table 17. Ranking of Global Top Non-muscle Invasive Bladder Cancer Therapeutics Companies by Revenue (US$ Million) in 2022
Table 18. Global 5 Largest Players Market Share by Non-muscle Invasive Bladder Cancer Therapeutics Revenue (CR5 and HHI) & (2018-2023)
Table 19. Key Players Headquarters and Area Served
Table 20. Key Players Non-muscle Invasive Bladder Cancer Therapeutics Product Solution and Service
Table 21. Date of Enter into Non-muscle Invasive Bladder Cancer Therapeutics Market
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Non-muscle Invasive Bladder Cancer Therapeutics Market Size by Type (2018-2023) & (US$ Million)
Table 24. Global Non-muscle Invasive Bladder Cancer Therapeutics Revenue Market Share by Type (2018-2023)
Table 25. Global Non-muscle Invasive Bladder Cancer Therapeutics Forecasted Market Size by Type (2024-2029) & (US$ Million)
Table 26. Global Non-muscle Invasive Bladder Cancer Therapeutics Revenue Market Share by Type (2024-2029)
Table 27. Global Non-muscle Invasive Bladder Cancer Therapeutics Market Size by Application (2018-2023) & (US$ Million)
Table 28. Global Non-muscle Invasive Bladder Cancer Therapeutics Revenue Market Share by Application (2018-2023)
Table 29. Global Non-muscle Invasive Bladder Cancer Therapeutics Forecasted Market Size by Application (2024-2029) & (US$ Million)
Table 30. Global Non-muscle Invasive Bladder Cancer Therapeutics Revenue Market Share by Application (2024-2029)
Table 31. North America Non-muscle Invasive Bladder Cancer Therapeutics Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 32. North America Non-muscle Invasive Bladder Cancer Therapeutics Market Size by Country (2018-2023) & (US$ Million)
Table 33. North America Non-muscle Invasive Bladder Cancer Therapeutics Market Size by Country (2024-2029) & (US$ Million)
Table 34. Europe Non-muscle Invasive Bladder Cancer Therapeutics Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 35. Europe Non-muscle Invasive Bladder Cancer Therapeutics Market Size by Country (2018-2023) & (US$ Million)
Table 36. Europe Non-muscle Invasive Bladder Cancer Therapeutics Market Size by Country (2024-2029) & (US$ Million)
Table 37. Asia-Pacific Non-muscle Invasive Bladder Cancer Therapeutics Market Size Growth Rate by Region (US$ Million): 2018 VS 2022 VS 2029
Table 38. Asia-Pacific Non-muscle Invasive Bladder Cancer Therapeutics Market Size by Region (2018-2023) & (US$ Million)
Table 39. Asia-Pacific Non-muscle Invasive Bladder Cancer Therapeutics Market Size by Region (2024-2029) & (US$ Million)
Table 40. Latin America Non-muscle Invasive Bladder Cancer Therapeutics Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 41. Latin America Non-muscle Invasive Bladder Cancer Therapeutics Market Size by Country (2018-2023) & (US$ Million)
Table 42. Latin America Non-muscle Invasive Bladder Cancer Therapeutics Market Size by Country (2024-2029) & (US$ Million)
Table 43. Middle East & Africa Non-muscle Invasive Bladder Cancer Therapeutics Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 44. Middle East & Africa Non-muscle Invasive Bladder Cancer Therapeutics Market Size by Country (2018-2023) & (US$ Million)
Table 45. Middle East & Africa Non-muscle Invasive Bladder Cancer Therapeutics Market Size by Country (2024-2029) & (US$ Million)
Table 46. F. Hoffmann-La Roche Ltd. Company Detail
Table 47. F. Hoffmann-La Roche Ltd. Business Overview
Table 48. F. Hoffmann-La Roche Ltd. Non-muscle Invasive Bladder Cancer Therapeutics Product
Table 49. F. Hoffmann-La Roche Ltd. Revenue in Non-muscle Invasive Bladder Cancer Therapeutics Business (2018-2023) & (US$ Million)
Table 50. F. Hoffmann-La Roche Ltd. Recent Development
Table 51. Bristol-Myers Squibb Company Company Detail
Table 52. Bristol-Myers Squibb Company Business Overview
Table 53. Bristol-Myers Squibb Company Non-muscle Invasive Bladder Cancer Therapeutics Product
Table 54. Bristol-Myers Squibb Company Revenue in Non-muscle Invasive Bladder Cancer Therapeutics Business (2018-2023) & (US$ Million)
Table 55. Bristol-Myers Squibb Company Recent Development
Table 56. AstraZeneca Company Detail
Table 57. AstraZeneca Business Overview
Table 58. AstraZeneca Non-muscle Invasive Bladder Cancer Therapeutics Product
Table 59. AstraZeneca Revenue in Non-muscle Invasive Bladder Cancer Therapeutics Business (2018-2023) & (US$ Million)
Table 60. AstraZeneca Recent Development
Table 61. Pfizer Inc. Company Detail
Table 62. Pfizer Inc. Business Overview
Table 63. Pfizer Inc. Non-muscle Invasive Bladder Cancer Therapeutics Product
Table 64. Pfizer Inc. Revenue in Non-muscle Invasive Bladder Cancer Therapeutics Business (2018-2023) & (US$ Million)
Table 65. Pfizer Inc. Recent Development
Table 66. GlaxoSmithKline plc. Company Detail
Table 67. GlaxoSmithKline plc. Business Overview
Table 68. GlaxoSmithKline plc. Non-muscle Invasive Bladder Cancer Therapeutics Product
Table 69. GlaxoSmithKline plc. Revenue in Non-muscle Invasive Bladder Cancer Therapeutics Business (2018-2023) & (US$ Million)
Table 70. GlaxoSmithKline plc. Recent Development
Table 71. Sanofi S.A. Company Detail
Table 72. Sanofi S.A. Business Overview
Table 73. Sanofi S.A. Non-muscle Invasive Bladder Cancer Therapeutics Product
Table 74. Sanofi S.A. Revenue in Non-muscle Invasive Bladder Cancer Therapeutics Business (2018-2023) & (US$ Million)
Table 75. Sanofi S.A. Recent Development
Table 76. Novartis AG Company Detail
Table 77. Novartis AG Business Overview
Table 78. Novartis AG Non-muscle Invasive Bladder Cancer Therapeutics Product
Table 79. Novartis AG Revenue in Non-muscle Invasive Bladder Cancer Therapeutics Business (2018-2023) & (US$ Million)
Table 80. Novartis AG Recent Development
Table 81. Eli Lilly and Company Company Detail
Table 82. Eli Lilly and Company Business Overview
Table 83. Eli Lilly and Company Non-muscle Invasive Bladder Cancer Therapeutics Product
Table 84. Eli Lilly and Company Revenue in Non-muscle Invasive Bladder Cancer Therapeutics Business (2018-2023) & (US$ Million)
Table 85. Eli Lilly and Company Recent Development
Table 86. Merck & Co. Company Detail
Table 87. Merck & Co. Business Overview
Table 88. Merck & Co. Non-muscle Invasive Bladder Cancer Therapeutics Product
Table 89. Merck & Co. Revenue in Non-muscle Invasive Bladder Cancer Therapeutics Business (2018-2023) & (US$ Million)
Table 90. Merck & Co. Recent Development
Table 91. Viventia Bio Inc. Company Detail
Table 92. Viventia Bio Inc. Business Overview
Table 93. Viventia Bio Inc. Non-muscle Invasive Bladder Cancer Therapeutics Product
Table 94. Viventia Bio Inc. Revenue in Non-muscle Invasive Bladder Cancer Therapeutics Business (2018-2023) & (US$ Million)
Table 95. Viventia Bio Inc. Recent Development
Table 96. Celgene Corporation Company Detail
Table 97. Celgene Corporation Business Overview
Table 98. Celgene Corporation Non-muscle Invasive Bladder Cancer Therapeutics Product
Table 99. Celgene Corporation Revenue in Non-muscle Invasive Bladder Cancer Therapeutics Business (2018-2023) & (US$ Million)
Table 100. Celgene Corporation Recent Development
Table 101. Spectrum Pharmaceuticals, Inc. Company Detail
Table 102. Spectrum Pharmaceuticals, Inc. Business Overview
Table 103. Spectrum Pharmaceuticals, Inc. Non-muscle Invasive Bladder Cancer Therapeutics Product
Table 104. Spectrum Pharmaceuticals, Inc. Revenue in Non-muscle Invasive Bladder Cancer Therapeutics Business (2018-2023) & (US$ Million)
Table 105. Spectrum Pharmaceuticals, Inc. Recent Development
Table 106. Herantis Pharma Plc. Company Detail
Table 107. Herantis Pharma Plc. Business Overview
Table 108. Herantis Pharma Plc. Non-muscle Invasive Bladder Cancer Therapeutics Product
Table 109. Herantis Pharma Plc. Revenue in Non-muscle Invasive Bladder Cancer Therapeutics Business (2018-2023) & (US$ Million)
Table 110. Herantis Pharma Plc. Recent Development
Table 111. Taris Biomedical LLC Company Detail
Table 112. Taris Biomedical LLC Business Overview
Table 113. Taris Biomedical LLC Non-muscle Invasive Bladder Cancer Therapeutics Product
Table 114. Taris Biomedical LLC Revenue in Non-muscle Invasive Bladder Cancer Therapeutics Business (2018-2023) & (US$ Million)
Table 115. Taris Biomedical LLC Recent Development
Table 116. Prometic Life Sciences Inc. Company Detail
Table 117. Prometic Life Sciences Inc. Business Overview
Table 118. Prometic Life Sciences Inc. Non-muscle Invasive Bladder Cancer Therapeutics Product
Table 119. Prometic Life Sciences Inc. Revenue in Non-muscle Invasive Bladder Cancer Therapeutics Business (2018-2023) & (US$ Million)
Table 120. Prometic Life Sciences Inc. Recent Development
Table 121. Telormediz S.A. Company Detail
Table 122. Telormediz S.A. Business Overview
Table 123. Telormediz S.A. Non-muscle Invasive Bladder Cancer Therapeutics Product
Table 124. Telormediz S.A. Revenue in Non-muscle Invasive Bladder Cancer Therapeutics Business (2018-2023) & (US$ Million)
Table 125. Telormediz S.A. Recent Development
Table 126. Heat Biologics Company Detail
Table 127. Heat Biologics Business Overview
Table 128. Heat Biologics Non-muscle Invasive Bladder Cancer Therapeutics Product
Table 129. Heat Biologics Revenue in Non-muscle Invasive Bladder Cancer Therapeutics Business (2018-2023) & (US$ Million)
Table 130. Heat Biologics Recent Development
Table 131. Altor BioScience Company Detail
Table 132. Altor BioScience Business Overview
Table 133. Altor BioScience Non-muscle Invasive Bladder Cancer Therapeutics Product
Table 134. Altor BioScience Revenue in Non-muscle Invasive Bladder Cancer Therapeutics Business (2018-2023) & (US$ Million)
Table 135. Altor BioScience Recent Development
Table 136. Ferring B.V. Company Detail
Table 137. Ferring B.V. Business Overview
Table 138. Ferring B.V. Non-muscle Invasive Bladder Cancer Therapeutics Product
Table 139. Ferring B.V. Revenue in Non-muscle Invasive Bladder Cancer Therapeutics Business (2018-2023) & (US$ Million)
Table 140. Ferring B.V. Recent Development
Table 141. Cold Genesys Inc. Company Detail
Table 142. Cold Genesys Inc. Business Overview
Table 143. Cold Genesys Inc. Non-muscle Invasive Bladder Cancer Therapeutics Product
Table 144. Cold Genesys Inc. Revenue in Non-muscle Invasive Bladder Cancer Therapeutics Business (2018-2023) & (US$ Million)
Table 145. Cold Genesys Inc. Recent Development
Table 146. Research Programs/Design for This Report
Table 147. Key Data Information from Secondary Sources
Table 148. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Non-muscle Invasive Bladder Cancer Therapeutics Market Size Comparison by Type (2023-2029) & (US$ Million)
Figure 2. Global Non-muscle Invasive Bladder Cancer Therapeutics Market Share by Type: 2022 VS 2029
Figure 3. Intravesical Chemotherapy Features
Figure 4. Intravesical Immunotherapy Features
Figure 5. Global Non-muscle Invasive Bladder Cancer Therapeutics Market Size Comparison by Application (2023-2029) & (US$ Million)
Figure 6. Global Non-muscle Invasive Bladder Cancer Therapeutics Market Share by Application: 2022 VS 2029
Figure 7. Hospital Case Studies
Figure 8. Ambulatory Surgery Center Case Studies
Figure 9. Others Case Studies
Figure 10. Non-muscle Invasive Bladder Cancer Therapeutics Report Years Considered
Figure 11. Global Non-muscle Invasive Bladder Cancer Therapeutics Market Size (US$ Million), Year-over-Year: 2018-2029
Figure 12. Global Non-muscle Invasive Bladder Cancer Therapeutics Market Size, (US$ Million), 2018 VS 2022 VS 2029
Figure 13. Global Non-muscle Invasive Bladder Cancer Therapeutics Market Share by Region: 2022 VS 2029
Figure 14. Global Non-muscle Invasive Bladder Cancer Therapeutics Market Share by Players in 2022
Figure 15. Global Top Non-muscle Invasive Bladder Cancer Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Non-muscle Invasive Bladder Cancer Therapeutics as of 2022)
Figure 16. The Top 10 and 5 Players Market Share by Non-muscle Invasive Bladder Cancer Therapeutics Revenue in 2022
Figure 17. North America Non-muscle Invasive Bladder Cancer Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 18. North America Non-muscle Invasive Bladder Cancer Therapeutics Market Share by Country (2018-2029)
Figure 19. United States Non-muscle Invasive Bladder Cancer Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 20. Canada Non-muscle Invasive Bladder Cancer Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 21. Europe Non-muscle Invasive Bladder Cancer Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 22. Europe Non-muscle Invasive Bladder Cancer Therapeutics Market Share by Country (2018-2029)
Figure 23. Germany Non-muscle Invasive Bladder Cancer Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 24. France Non-muscle Invasive Bladder Cancer Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 25. U.K. Non-muscle Invasive Bladder Cancer Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 26. Italy Non-muscle Invasive Bladder Cancer Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 27. Russia Non-muscle Invasive Bladder Cancer Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 28. Nordic Countries Non-muscle Invasive Bladder Cancer Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 29. Asia-Pacific Non-muscle Invasive Bladder Cancer Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 30. Asia-Pacific Non-muscle Invasive Bladder Cancer Therapeutics Market Share by Region (2018-2029)
Figure 31. China Non-muscle Invasive Bladder Cancer Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 32. Japan Non-muscle Invasive Bladder Cancer Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 33. South Korea Non-muscle Invasive Bladder Cancer Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 34. Southeast Asia Non-muscle Invasive Bladder Cancer Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 35. India Non-muscle Invasive Bladder Cancer Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 36. Australia Non-muscle Invasive Bladder Cancer Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 37. Latin America Non-muscle Invasive Bladder Cancer Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 38. Latin America Non-muscle Invasive Bladder Cancer Therapeutics Market Share by Country (2018-2029)
Figure 39. Mexico Non-muscle Invasive Bladder Cancer Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 40. Brazil Non-muscle Invasive Bladder Cancer Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 41. Middle East & Africa Non-muscle Invasive Bladder Cancer Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 42. Middle East & Africa Non-muscle Invasive Bladder Cancer Therapeutics Market Share by Country (2018-2029)
Figure 43. Turkey Non-muscle Invasive Bladder Cancer Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 44. Saudi Arabia Non-muscle Invasive Bladder Cancer Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 45. F. Hoffmann-La Roche Ltd. Revenue Growth Rate in Non-muscle Invasive Bladder Cancer Therapeutics Business (2018-2023)
Figure 46. Bristol-Myers Squibb Company Revenue Growth Rate in Non-muscle Invasive Bladder Cancer Therapeutics Business (2018-2023)
Figure 47. AstraZeneca Revenue Growth Rate in Non-muscle Invasive Bladder Cancer Therapeutics Business (2018-2023)
Figure 48. Pfizer Inc. Revenue Growth Rate in Non-muscle Invasive Bladder Cancer Therapeutics Business (2018-2023)
Figure 49. GlaxoSmithKline plc. Revenue Growth Rate in Non-muscle Invasive Bladder Cancer Therapeutics Business (2018-2023)
Figure 50. Sanofi S.A. Revenue Growth Rate in Non-muscle Invasive Bladder Cancer Therapeutics Business (2018-2023)
Figure 51. Novartis AG Revenue Growth Rate in Non-muscle Invasive Bladder Cancer Therapeutics Business (2018-2023)
Figure 52. Eli Lilly and Company Revenue Growth Rate in Non-muscle Invasive Bladder Cancer Therapeutics Business (2018-2023)
Figure 53. Merck & Co. Revenue Growth Rate in Non-muscle Invasive Bladder Cancer Therapeutics Business (2018-2023)
Figure 54. Viventia Bio Inc. Revenue Growth Rate in Non-muscle Invasive Bladder Cancer Therapeutics Business (2018-2023)
Figure 55. Celgene Corporation Revenue Growth Rate in Non-muscle Invasive Bladder Cancer Therapeutics Business (2018-2023)
Figure 56. Spectrum Pharmaceuticals, Inc. Revenue Growth Rate in Non-muscle Invasive Bladder Cancer Therapeutics Business (2018-2023)
Figure 57. Herantis Pharma Plc. Revenue Growth Rate in Non-muscle Invasive Bladder Cancer Therapeutics Business (2018-2023)
Figure 58. Taris Biomedical LLC Revenue Growth Rate in Non-muscle Invasive Bladder Cancer Therapeutics Business (2018-2023)
Figure 59. Prometic Life Sciences Inc. Revenue Growth Rate in Non-muscle Invasive Bladder Cancer Therapeutics Business (2018-2023)
Figure 60. Telormediz S.A. Revenue Growth Rate in Non-muscle Invasive Bladder Cancer Therapeutics Business (2018-2023)
Figure 61. Heat Biologics Revenue Growth Rate in Non-muscle Invasive Bladder Cancer Therapeutics Business (2018-2023)
Figure 62. Altor BioScience Revenue Growth Rate in Non-muscle Invasive Bladder Cancer Therapeutics Business (2018-2023)
Figure 63. Ferring B.V. Revenue Growth Rate in Non-muscle Invasive Bladder Cancer Therapeutics Business (2018-2023)
Figure 64. Cold Genesys Inc. Revenue Growth Rate in Non-muscle Invasive Bladder Cancer Therapeutics Business (2018-2023)
Figure 65. Bottom-up and Top-down Approaches for This Report
Figure 66. Data Triangulation
Figure 67. Key Executives Interviewed


*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
※関連調査資料
  • 非侵襲的美容治療製品の世界市場2023年：ボトックス/皮膚フィラー、レーザー脱毛器、高周波/超音波器、糸、その他
  • 膀胱がん標的療法のグローバル市場展望 2023年-2029年：アテゾリズマブ（テセントリク）、アベルマブ（バベンシオ）、エルダフィチニブ（バルバーサ）、その他
  • 免疫細胞療法の世界市場2023年：T細胞療法、ナチュラルキラー（NK）細胞療法、その他
  • ヘリコバクターピロリ非侵襲的検査の世界市場2023年：血清学的検査、尿素呼気検査（UBT）、便潜血検査（SAT）
  • 侵襲性真菌感染症診断の世界市場2023年：ガラクトマンナン（GM）試験、（1,3）-β-D-グルカン（G）試験
    • ※注目の調査資料
     ※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
    ※当市場調査資料(QYR23MA7515 )"非筋層浸潤性膀胱がん治療薬の世界市場2023年：膀胱内化学療法、膀胱内免疫療法" (英文：Global Non-muscle Invasive Bladder Cancer Therapeutics Market Research Report 2023)はQYResearch社が調査・発行しており、H&Iグローバルリサーチが販売します。

    ◆H&Iグローバルリサーチのお客様（例）◆


    ※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
    ※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。